India Pharma Outlook Team | Friday, 07 November 2025
Zydus?????? Lifesciences Ltd. is set to broaden its US specialty sector with non-core molecules composition Saroglitazar. The company has a plan to use the funds from its recently approved ?5,000-crore Qualified Institutional Placement (QIP) to finance the expansion.
To stay ahead of the competition, the company envisions the acquisition of innovative assets and strategic purchasing as a means to achieve its growth pipeline.
On an investor call with Dr. Sharvil Patel, Zydus Lifesciences' Managing Director said the QIP would reduce debt on the balance sheet, improve capital structure, and increase the company's capacity to seize new opportunities.
"The US specialty business, primarily in gastroenterology, where we are considering strategic acquisitions, is still our main focus. We have also identified CNS and interventional cardiology segments as areas of potential," Dr. Patel mentioned.
Also Read: Apollo Hospitals Q2 Revenue Rises 13% to Rs 6,304 Crore
Indications are that Zydus' novel PPAR alpha/gamma agonist, Saroglitazar, will be debuting its primary biliary cholangitis (PBC) therapy in the market within a year or so after completion of its Phase 3 trials. According to the US FDA, the therapy is given the Orphan Drug and Fast Track Designation, and it showed safety and efficacy in clinical trials.
By Zydus's post-launch activity plan, they would like to strengthen their commercial presence by employing 50–80 field representatives and exploring local partnership for those market where they don’t have direct access.
Saroglitazar making a strong position for Zydus, against Gilead’s Livdelzi and Ipsen’s Iqirvo, as a viable candidate in rare liver disease therapeutics and at the same time a leading signal of the company's strategic shift to high-value specialty and innovation-driven ??????growth.
.jpg)
